In this randomised, placebo-controlled study of 37 people with major depressive disorder, a single moderate dose of psilocybin (0.215 mg/kg), alongside psychological support, produced significantly greater reductions in depressive symptoms at two weeks than placebo. Participants also showed improvements across six aspects of positive self-concept, including self-esteem, problem-solving, confidence in decision-making and relationships with others. Improvements in self-concept were associated with reductions in depression, suggesting that changes in how individuals perceive themselves may be relevant to therapeutic outcomes. Functional MRI also identified changes in caudate activity during externally directed attention and self-referential processing, although these changes were not directly associated with symptom improvement. The findings highlight the potential importance of self-perception in psychedelic-assisted therapy, although the small sample and short follow-up limit conclusions about longer-term effects.
Abstract
Psychedelic-assisted therapy, particularly with psilocybin, is increasingly proposed as a treatment for major depressive disorder, yet the neural and psychological mechanisms underlying its effects remain under investigation. In a randomized, double-blind, placebo-controlled clinical trial, individuals diagnosed with major depressive disorder received a single, moderate dose of psilocybin (0.215 mg kg-1) or placebo, with the same psychological support. We analysed N = 37 individuals with major depressive disorder undergoing assessments of depressive symptoms (Beck's depression inventory and Montgomery-Åsberg depression rating scale), self-concept (Frankfurt self-concept scale) and neural markers of self-referential processing using an fMRI-based task. Compared with placebo, the psilocybin group exhibited significant reductions in depressive symptoms and a significant increase in positive self-concept two weeks after substance administration. Changes in self-concept were significantly correlated with decreased depressive scores. Neuroimaging revealed psilocybin-associated modulation of caudate activation during externally oriented attention after two weeks, contrasting with placebo-induced caudate changes during self-referential processing. These findings extend prior evidence linking psychedelics to changes in self-referential processing and self-concept and demonstrate that such changes occur concurrently with reductions in depressive symptoms. Future research should aim to replicate and extend these results and refine therapy protocols targeting self-processing and self-concept in psychedelic-assisted therapy in major depressive disorder. This article is part of the discussion meeting issue 'From being to identity: analysis and synthesis of the self'.
Belinger L, Moujaes F, von Rotz R, Rieser NM, Funk X, Egger K, Meinhold L, Renkert M, Stämpfli P, Herdener M, Vollenweider FX, Preller KH. Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients. Philos Trans R Soc Lond B Biol Sci. 2026 Nov 10;381(1962):20250168. doi: 10.1098/rstb.2025.0168. PMID: 43007824; PMCID: PMC13750421. Read Paper